{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/antiplatelet-treatment/background-information/indications/","result":{"pageContext":{"chapter":{"id":"ef9f4561-2787-59c9-974b-b656929c553c","slug":"indications","fullItemName":"Indications","depth":2,"htmlHeader":"<!-- begin field aeafe8ac-c862-4d3c-9715-a78100875343 --><h2>What are the indications for antiplatelet treatment?</h2><!-- end field aeafe8ac-c862-4d3c-9715-a78100875343 -->","summary":"","htmlStringContent":"<!-- begin item d9d51ef3-3601-418f-9f2d-a78100875230 --><!-- begin field 2ae14f3b-40b5-4770-9761-a78100875343 --><ul><li><strong>Antiplatelet treatments are given for:</strong><ul><li><strong>The primary prevention of atherothrombotic events</strong> in people who are at high risk. </li><li><strong>The secondary prevention of atherothrombotic events</strong> in people with:<ul><li>Acute coronary syndrome (ACS).</li><li>Angina.</li><li>Peripheral arterial disease.</li><li>Atrial fibrillation (AF) — in some people, although anticoagulants are more usually prescribed.</li></ul></li><li><strong>The secondary prevention of cardiovascular events in people after:</strong><ul><li>Myocardial infarction (MI).</li><li>Stent implantation.</li><li>Stroke or transient ischaemic attack.</li></ul></li><li><strong>The prevention of atherothrombotic events in people undergoing percutaneous coronary intervention (PCI). </strong></li></ul></li><li><strong>Aspirin</strong> is indicated for:<ul><li>Acute MI.</li><li>Secondary prevention of MI, transient ischaemic attacks (TIA) and ischaemic cerebrovascular accidents (CVA).</li><li>Stable angina pectoris, or history of unstable angina pectoris, except during the acute phase.</li><li>Prevention of graft occlusion after coronary artery bypass grafting (CABG).</li><li>Coronary angioplasty, except during the acute phase.</li><li><strong>Note:</strong> use of aspirin in primary prevention of cardiovascular events in people with or without diabetes mellitus is of unproven benefit.</li></ul></li><li><strong>Aspirin</strong> is also indicated for people with AF, intermittent claudication, and following insertion of coronary stents.</li><li><strong>Clopidogrel </strong>is licensed for prevention of<strong> </strong>atherothrombotic events in people with a history of symptomatic ischaemic disease.</li><li><strong>Clopidogrel</strong> in combination with low-dose aspirin is licensed for: <ul><li>ACS without ST-segment elevation.</li><li>Acute MI with ST-segment elevation.</li><li>Prevention of atherothrombotic and thromboembolic events in people with AF (and at least one risk factor for a vascular event), and for whom warfarin is unsuitable.</li></ul></li><li><strong>Clopidogrel</strong> is also indicated for stroke, and as an adjunct with aspirin in people undergoing percutaneous coronary intervention (PCI).</li><li><strong>Dipyridamole </strong>is used as an adjunct to oral anticoagulation for prophylaxis of thromboembolism associated with prosthetic heart valves.<ul><li>Modified-release preparations are licensed for secondary prevention of ischaemic stroke and TIA.</li></ul></li><li><strong>Prasugrel</strong> in combination with aspirin, is licensed for the prevention of atherothrombotic events in people with ACS undergoing PCI. </li><li><strong>Ticagrelor</strong> in combination with aspirin, is licensed for the prevention of atherothrombotic events in people with ACS, or a history of MI and a high risk of developing an atherothrombotic event.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ABPI, 2017e</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ABPI, 2017c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ABPI, 2017d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">BNF 75, 2018</a>]</p><!-- end field 2ae14f3b-40b5-4770-9761-a78100875343 --><!-- end item d9d51ef3-3601-418f-9f2d-a78100875230 -->","topic":{"id":"86dfa76b-bc1a-5d4b-bf7c-018d5d031947","topicId":"a68e1521-d84e-4abb-bb17-6186ba7a891a","topicName":"Antiplatelet treatment","slug":"antiplatelet-treatment","lastRevised":"Last revised in August 2020","chapters":[{"id":"af85e41e-4007-5daa-bc95-35aa03621ea0","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"db8ef934-0123-530e-9f34-52d23ea99e56","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"ebaf9360-bb92-51bc-8aba-ac3293fa1416","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"b34f13e6-85f8-5c85-b2f7-5678c0779a07","slug":"changes","fullItemName":"Changes"},{"id":"9532ea0d-f7f7-5a08-9076-dedbf78ca97d","slug":"update","fullItemName":"Update"}]},{"id":"0370616e-85d0-5654-b5ad-ea9980ad8eaa","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"24bebba9-1157-505c-834d-bf255dd856a9","slug":"goals","fullItemName":"Goals"},{"id":"b1ab86f3-b045-5a24-b8ea-506ae6fa94c8","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"cb61b0c8-a7f6-5e31-af33-9c4ade31a493","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"19dcf0a2-d60c-5fe4-94b7-d902d7cc17f8","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"758947ec-f9bc-59c9-a07f-663f738f5428","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8c16356c-f5cf-54fc-99e8-ccc08af83ec7","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"30e0cacd-1816-520e-8f4a-aba760ce71f5","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"9e23a119-ae6d-5e11-9691-ed23c4016c39","slug":"definition","fullItemName":"Definition"},{"id":"2ef5b7fd-3211-5769-8a72-083d9f8c40c8","slug":"mechanism-of-action","fullItemName":"Mechanism of action"},{"id":"ef9f4561-2787-59c9-974b-b656929c553c","slug":"indications","fullItemName":"Indications"},{"id":"7692771a-8763-57f6-b4fe-d4711f820cfb","slug":"complications","fullItemName":"Complications"}]},{"id":"d31d1a85-d8c2-5598-b7e0-e8b2da36e45c","fullItemName":"Management","slug":"management","subChapters":[{"id":"81844a0f-b280-563a-b66c-4a5dba6e1e9c","slug":"primary-prevention-of-cvd","fullItemName":"Scenario: Primary prevention of CVD"},{"id":"c2fb4ffa-788d-5d77-a694-3e30c3008d35","slug":"secondary-prevention-of-cvd","fullItemName":"Scenario: Secondary prevention of CVD"}]},{"id":"85828cd6-6943-58a7-9657-71760be76497","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"d408bf47-147e-5914-ab35-c4142ec2a33e","slug":"low-dose-aspirin","fullItemName":"Low dose aspirin"},{"id":"4098d4bf-7db2-5e79-bdec-17a2bbfaca6a","slug":"clopidogrel","fullItemName":"Clopidogrel"},{"id":"d5d8e5ca-9f57-5ac9-955b-614b85700f3e","slug":"dipyridamole","fullItemName":"Dipyridamole"},{"id":"52159350-4f8e-536b-99c4-a75908d6233a","slug":"prasugrel","fullItemName":"Prasugrel"},{"id":"92100407-8f08-53c0-8df1-1e802f4dcbe9","slug":"ticagrelor","fullItemName":"Ticagrelor"}]},{"id":"ec007ae2-2b14-50b1-a091-3875c81c5adb","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"f54cfffb-be9e-5523-a47f-c1100845c9c4","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"4ce7f1c7-df35-54c7-9f8b-b1aefe5762f1","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f4d603b9-b19a-53ac-8058-8c414be0a10b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"69fb4d5c-2946-5ef6-8c7f-b5f81dd52f9c","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d1e16069-862f-500a-9f58-e84cb201da64","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"fab694fa-9176-5402-b7b5-729a22dd611f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"3852e22b-c968-5afe-81be-ac1efce390da","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"30e0cacd-1816-520e-8f4a-aba760ce71f5","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}